Vitae Pharmaceuticals (VTAE) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
March 3, 2016 4:06 PM ESTProof-of-concept data for VTP-43742 expected in the first quarter of 2016
Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis
Conference call scheduled for 4:30 p.m. EST today
FORT WASHINGTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the fourth quarter and full year ended December 31, 2015.
Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, Our accomplishments during the fourth quarter and full year of 2015... More
